



# The relationship between different subtypes of *KRAS* and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients

Ying Yang<sup>1#</sup>, Shengping Shen<sup>1#</sup>, Yingjia Sun<sup>1</sup>, Hatim Husain<sup>2</sup>, Haiyan Zhou<sup>3</sup>, Shun Lu<sup>1</sup>, Ziming Li<sup>1</sup>

<sup>1</sup>Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China; <sup>2</sup>University of California San Diego, La Jolla, CA, USA; <sup>3</sup>Department of Industry Office, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

**Contributions:** (I) Conception and design: Y Sun, Z Li, S Lu; (II) Administrative support: Z Li, S Lu; (III) Provision of study materials or patients: Z Li, S Lu; (IV) Collection and assembly of data: Y Yang, S Shen; (V) Data analysis and interpretation: Y Yang, S Shen; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

<sup>#</sup>These authors contributed equally to this work.

**Correspondence to:** Haiyan Zhou. Department of Industry Office, Shanghai Chest Hospital, Shanghai Jiao Tong University, West Huaihai Road 241, Shanghai 200030, China. Email: 812358534@qq.com; Shun Lu, PhD, MD. Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, West Huaihai Road 241, Shanghai 200030, China. Email: shunlu@sjtu.edu.cn; Ziming Li, PhD. Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, West Huaihai Road 241, Shanghai 200030, China. Email: liziming1980@163.com.

**Background:** *KRAS* gene mutations are the most common driver oncogenes in non-small cell lung cancer (NSCLC). We conducted an analysis of the immunological characteristics including tumor mutation burden and programmed death-ligand 1 (PD-L1) expression of different subtypes of *KRAS* in 2880 *KRAS*-mutant NSCLC patients.

**Methods:** A total of 2,880 patients with NSCLC were included in the study. Somatic mutation data were provided by Berry Oncology (Fujian, China), Geneplus BioTech (Beijing, China), Nanjing Geneseeq Technology Inc (Nanjing, China), and Burning Rock Biotech (Guangzhou, China). Z-scores were used to unify all data. SPSS 20.0 (SPSS, Chicago, IL, USA) software was used for statistical analyses. All scatter plots and boxplot maps were drawn using GraphPad Prism 8. Tumor mutation burden (TMB) expression was defined by the number of somatic mutations. The PD-L1 clone 22C3 pharmDx kit was used to measure the expression level of PD-L1. Mann-Whitney U test was used for statistical analysis. P value <0.05 was considered statistically significant.

**Results:** We identified 2,880 patients with *KRAS*-mutant NSCLC. The percentage level of TMB and expression of PD-L1 was significantly decreased in *KRAS* *Q61X*-mutant lung cancer tissue and blood samples (n=162). The percentage level of TMB and expression of PD-L1 in *KRAS* *G13X*-mutant lung cancer specimens was significantly increased (n=190).

**Conclusions:** The findings demonstrate a decreased level of TMB and expression of PD-L1 in *KRAS* *Q61X*-mutant lung cancer and the increased level of TMB and expression of PD-L1 in *KRAS* *G13X*-mutant lung cancer. Further work is needed to identify if the subtype of *KRAS* mutation could be a potential therapeutic biomarker in lung cancer patients with *KRAS* mutation. TMB data was consistently verified in tissue and blood samples and confirmed the feasibility of next-generation sequencing (NGS) verification in plasma samples. Our research may help to provide more individualized treatment options for NSCLC patients.

**Keywords:** Tumor mutation burden (TMB); programmed death-ligand 1 (PD-L1); non-small cell lung cancer (NSCLC); *KRAS* *Q61X* mutation; *KRAS* *G13X* mutation

Submitted Dec 17, 2021. Accepted for publication Feb 21, 2022.

doi: 10.21037/tlcr-22-88

**View this article at:** <https://dx.doi.org/10.21037/tlcr-22-88>

## Introduction

Lung cancer is a leading cause of cancer-related deaths worldwide (1). *KRAS*, the most common oncogene, has been found in 26.1% of lung adenocarcinomas (LADCs) and 6.4% of squamous cell carcinomas (SQCCs) in Western countries and in 11.2% and 1.8% of lung cancer cases in Asia, respectively (2,3). Tumors with *KRAS* mutation are some of the most invasive and refractory types of tumors. *KRAS* mutations have a higher prevalence in Western countries and in smokers (4).


Targeted drugs have been developed for non-small cell lung cancer (NSCLC) to inhibit tumor proliferation and invasion. The discovery of targeted therapies for patients with epidermal growth factor receptor (*EGFR*) mutation and anaplastic lymphoma kinase (*ALK*) or c-ros oncogene 1 (*ROS1*) rearrangements has been a breakthrough in the treatment history of NSCLC (5-9). However, for many years, effective *KRAS*-targeted therapies have been limited with only recent approvals for the *KRAS G12C* isoform in lung cancer.

The *RAS* gene family encodes enzymes to hydrolyze GTPase, linking upstream cell surface receptors such as *EGFR* and fibroblast growth factor receptor (*FGFR*) to downstream survival and proliferation pathways, including Raf/mitogen-activated protein kinase (*MEK*)/extracellular signal-regulated kinase (*ERK*), phosphatidylinositol-3 kinase (*PI3K*)/protein kinase B (*AKT*)/mammalian target of rapamycin (mTOR), and Ral guanine nucleotide dissociation stimulator (RalGDS)/RA (4). As the most common oncogene, *KRAS*, *HRAS*, and *NRAS* mutations occur in 30% of cancer cases. *KRAS* is the most common mutation subtype, present in 86% of *RAS* mutations in cancer, followed by *NRAS* (11%), and *HRAS* (3%) (8). *RAS* has the highest modification rate in lung, pancreatic, and colorectal cancer, and *KRAS* is the most common in lung, pancreas, and colon cancer (8). *KRAS* mutations usually occur at codons 12, 13, and 61, and the most common codon mutations include *G12C* (GGT to TGT), *G12V* (GGT to GTT), and *G12D* (10). The subtypes of *KRAS* have been shown to drive different biological characteristics (11). Patients with p.*G12V* or p.*G12C* have been reported to have longer survival than those with other types of mutations (12-14). Patients who have never smoked are more common in *G12D* subtypes. The transition mutations (G→T or G→C) are more common in smokers, and transition mutations (G→A) are more common in never-smokers.

*KRAS* mutation is classically defined as a negative prognostic factor. *KRAS*-mutant lung cancer has poorer

survival and disease-free survival compared to *KRAS* wild-type tumors in both early stage and advanced metastatic lung cancer patients, indicating the urgent need for novel treatment strategies for *KRAS*-driven NSCLC (15). The *KRAS G12C* inhibitor sotorasib (AMG510) was recently approved by the US Food and Drug Administration (FDA) (16-18). The current standard options for patients with *KRAS* mutations include chemotherapy and/or checkpoint immunotherapy. Immunotherapy has advanced tumor treatment strategies, and patients with *KRAS* mutations may in some cases have increased immune response. The oncogene-specific differences are demonstrated in the expression of TMB and PD-L. NSCLC with *BRAF* mutations demonstrated superior benefit of ICB, which may be attributed to higher TMB and higher PD-L1 expression (19). A systematic meta-analysis demonstrated that patients with *KRAS* mutations show clinical benefits from the anti-PD-1/PD-L1 immunotherapy (20). Studies have shown that *KRAS* mutations are associated with the inflammatory tumor microenvironment and tumor immunogenicity, leading to better patient responses to PD-1 inhibitors. Subgroup analyses of clinical trial have indicated that the *KRAS*-mutant patients are more sensitive to PD-1/PD-L1 inhibitors than the wild-type (21-23). However, two recent studies have provided further insights into the predictive potential of *KRAS* mutations, concluding that *KRAS* Mutation status did not differ significantly in objective response rate (ORR), progression-free survival (PFS), or OS. The different subtypes of *KRAS* mutations may be associated with distinct therapeutic effects, and some may not benefit from immunotherapy (24,25). About half of *KRAS*-mutant NSCLCs have been found to harbor concomitant mutations, including *TP53*, *STK11*, and *CDKN2A/B* (26,27). One study demonstrated the potential predictive value of *TP53* and *KRAS* mutation for response to programmed cell death 1 (PD-1) blockade immunotherapy in lung adenocarcinoma (28). Objective response rates to PD-1 blockade differed significantly among *STK11/LKB1* & *KRAS* (7.4%), *TP53* & *KRAS* (35.7%), and *KRAS*-only (28.6%) (29). It has also been reported that *KRAS G12D* mutation predicts lower tumor mutation burden (TMB) and indicates immune suppression in LADC.

Therefore, we aimed to explore the expression level of TMB and programmed death-ligand 1 (PD-L1) in patients with *KRAS* mutant subtypes, providing more evidence for the response of *KRAS* mutant subtypes to immunotherapy. We conducted analysis of 2880 *KRAS*-mutant NSCLC patients who had PD-L1 testing performed and next



**Figure 1** *KRAS*-mutant non-small cell lung cancer prevalence in Chinese patients. (A) The frequency of *KRAS* subtype mutation in tissues of 2,880 non-small cell lung cancer (NSCLC) patients; (B) the frequency of *KRAS* subtype mutation in blood of 758 NSCLC patients.

generation sequencing performed for TMB testing.

We present the following article in accordance with the MDAR reporting checklist (available at <https://tclr.amegroups.com/article/view/10.21037/tclr-22-88/rc>).

## Methods

### Data collection and preparation

A total of 2,880 NSCLC patients in East China were included in the study. The data were provided by Berry Oncology (Fujian, China), Geneplus BioTech (Beijing, China), Nanjing Geneseeq Technology Inc (Nanjing, China), and Burning Rock Biotech (Guangzhou, China). TMB expression was defined by the number of somatic mutations (besides intron mutation and synonymous mutation) per genome area for target sequencing (38 Mb). Somatic mutations were defined as nonsynonymous mutations, non-silent mutations, deletion mutations, insertion mutations, and frameshift mutations. The PD-L1 clone 22C3 pharmDx kit was used to measure the expression level of PD-L1.

The study was approved by the institutional review board at Shanghai Jiao Tong University, Shanghai Chest Hospital (No. IS21126). It was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Individual consent for this retrospective analysis was waived.

### Statistical analyses

Z-scores were calculated by  $(x-\mu)/\sigma$  to convert 2 or more sets of data into unitless scores. SPSS 20.0 (SPSS, Chicago, IL, USA) software was used for statistical analyses. All scatter plots and boxplot maps were drawn using GraphPad Prism 8. Mann-Whitney U test was used for


statistical analysis. P value <0.05 was considered statistically significant.

## Results

### Clinical characteristics of Chinese *KRAS*-mutant NSCLC patients

To investigate TMB in *KRAS*-mutant NSCLC, we interrogated detailed somatic mutation data of NSCLC in tissues (2,880 cases) and blood (758 cases). Z-scores were used to unify all data. The prevalence of main mutations in 2880 patients with NSCLC is summarized in *Figure 1A*. Of the 2880 NSCLC patients harboring *KRAS* mutations, *KRAS p.A146X* was detected in 37 (1.2%) patients. The most frequent mutations found in *KRAS*-MUT patients were p.*G12C* (n=904, 31.4%) and p.*G12D* (n=523, 18.2%). The proportions of the other 2 major p.*G12* subtypes were *G12V*, 15.5% (n=447) and *G12A*, 7.3% (n=210). The proportion of *G13C* and *G13D* was 3% (n=87) and 3.3% (n=94), respectively. *Q61X* accounted for 5.5% of *KRAS* mutations, and *Q61H*, *Q61K*, *Q61L*, and *Q61R* accounted for 4.2%, 0.3%, 0.8%, and 0.2%, respectively (*Figure 1A*).

We screened blood samples from 758 NSCLC patients with *KRAS* mutation. *A146X* was detected in 13 (1.8%) patients. The most frequent mutations found in *KRAS*-MUT patients were p.*G12C* (n=227, 29.9%) and p.*G12D* (n=144, 19%). The proportions of the other 2 major p.*G12* subtypes were *G12V*, 15.7% (n=119) and *G12A*, 6.7% (n=51). The proportion of *G13C* and *G13D* was 3.7% (n=28) and 3.2% (n=24), respectively. *Q61X* accounted for 6.4% of *KRAS* mutations, and *Q61H*, *Q61K*, *Q61L*, and *Q61R* accounted for 4.4%, 0.4%, 1.1%, and 0.5%, respectively (*Figure 1B*).



**Figure 2** Tissue tumor mutation burden (TMB) across *KRAS* genotype. (A) The expression level of TMB in *KRAS* subtype mutations, including *A146X*, *A59X*, *G12X*, *G13X*, and *Q61X* (n=2,880); (B) the expression level of TMB in *KRAS* *G12X* mutation (n=2,222); (C) the expression level of TMB in *KRAS* *G13X* mutation (n=190); (D) the expression level of TMB in *KRAS* *Q61X* mutation (n=162); (E) the expression level of TMB in *KRAS* *A146X* mutation (n=37). \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.0001$ .

### TMB in tissue across *KRAS* genotypes

TMB expression was analyzed in the tissues of 2880 *KRAS*-MUT patients, including *A146X* (Z-score of TMB = 0.04), *A59X* (Z-score of TMB = 0.37), *G12X* (Z-score of TMB = -0.02), *G13X* (Z-score of TMB = 0.35), and *Q61X* (Z-score of TMB = -0.28). Z-scores were calculated by  $(x-\mu)/\sigma$  to convert 2 or more sets of data into unitless scores. We found that TMB expression in *KRAS* p.*Q61X* mutation was at a lower level (Z-score of TMB = -0.28). Meanwhile, *KRAS* p.*A59X* (Z-score of TMB = 0.37) and *KRAS* p.*G13X* (Z-score of TMB = 0.35) showed higher TMB expression (Figure 2A).


Among the 2,880 patients with *KRAS* mutation, p.*G12X* patients accounted for 77.2% (2,222). TMB expression in p.*G12L* was the highest (Z-score of TMB = 0.77), followed by p.*G12F* (Z-score of TMB = 0.14) and p.*G12C* (Z-score of TMB = 0.14). TMB expression in p.*G12D* was the lowest of p.*G12X* type (Z-score of TMB = -0.26, Figure 2B). There was no significant difference in TMB expression between p.*G13C* and p.*G13D* in patients with p.*G13* mutation

(n=190) (Figure 2C). Among the patients with p.*Q61X* mutation (n=162), TMB expression in p.*Q61K* was the lowest (Z-score of TMB = -0.58) and TMB expression in p.*Q61L* (Z-score of TMB = 0.20) was the highest (p.*Q61L* vs. p.*Q61K*,  $P = 0.01$ ) (Figure 2D). There was also no significant difference between p.*A146T* and p.*A146V* in patients with *A146* mutation (n=37) (Figure 2E).

### *KRAS* *Q61X* mutation showed decreased TMB in blood

TMB expression was also analyzed in blood samples of 758 *KRAS*-MUT patients, including *A146X* (Z-score of TMB = -0.15), *G12X* (Z-score of TMB = -0.06), *G13X* (Z-score of TMB = 0.50), and *Q61X* (Z-score of TMB = -2.6). The expression level of TMB in *G13X* was the highest, and TMB expression in *Q61X* was the lowest. Patients with *G13X* mutation might have a better response to immunotherapy, while patients with *Q61X* mutation may have poorer response to immunotherapy (Figure 3A).

TMB expression in p.*G12D* (Z-score of TMB = -1.9)



**Figure 3** Plasma tumor mutation burden (TMB) across *KRAS* genotype. (A) The expression level of TMB in *KRAS* subtype mutations, including *A146X*, *A59X*, *G12X*, *G13X*, and *Q61X* (n=758); (B) the expression level of TMB in *KRAS* *G12X* mutation (n=579); (C) the expression level of TMB in *KRAS* *G13X* mutation (n=54); (D) the expression level of TMB in *KRAS* *Q61X* mutation (n=55); (E) the expression level of TMB in *KRAS* *A146X* mutation (n=30). \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .

was the lowest of the p.*G12* mutation type. There was no significant difference among genotype in blood samples (Figure 3B). There was no significant difference in TMB expression between *G13C* and *G13D* in patients with *G13* mutation (n=54) (Figure 3C). Among the patients with *Q61* mutation (n=55), TMB expression in *Q61K* (Z-score of TMB = -0.62) was the lowest, and TMB expression in *Q61L* (Z-score of TMB = 0.11) was the highest (*Q61L* vs. *Q61K*  $P = 0.01$ ) (Figure 3D). There was also no significant difference between *A146T* and *A146V* in patients with *A146* mutation (n=30) (Figure 3E). In conclusion, the blood analysis results provide support for the conclusions of the tissue analysis.

#### ***KRAS* *Q61X* mutation showed decreased PD-L1 in tissue**

The expression of PD-L1 in NSCLC patients with *KRAS* mutation was also screened (Figure S1, n=412), including *A146X* (TPS = 16.33%), *G12X* (TPS = 27.25%), *G13X* (TPS = 35.21%), and *Q61X* (TPS = 12.82%) (Figure 4A). The


expression of PD-L1 in the *Q61X* mutation was at a lower level (TPS = 12.82%) (Figure 4B,4C).

A positive correlation between TMB and PD-L1 was confirmed (Figure 4D). The proportion of patients with PD-L1 expression greater than 50% in each *KRAS* mutation subtype was further analyzed. The proportion of patients with high PD-L1 [tumor proportion score (TPS)  $\geq 50\%$ ] expression in *G13X* and *Q61X* was 46.43% (n=13/28) and 16% (n=4/25), respectively (Figure 4E). In conclusion, the proportion of patients with high PD-L1 expression in *G13X*-MUT was significantly higher than that of *Q61X*-MUT patients.

#### ***The composition ratio of G13X in KRAS/TP53 co-mutation is significantly higher than Q61X in tissue***

The clinical data from Burning Rock Biotech (Guangzhou, China) were analyzed (n=155). The patients were divided into 4 groups: *KRAS/TP53*, *KRAS/STK11*, *KRAS/CDKN2A*, and *KRAS* mutation (without *TP53*, *STK11*,





**Figure 4** Tissue programmed death-ligand 1 (PD-L1) across *KRAS* genotype. (A) The frequency of *KRAS* subtype mutation in tissues of 412 non-small cell lung cancer (NSCLC) patients. PD-L1 protein expression was evaluated by immunohistochemistry (IHC). The PD-L1 clone 22C3 pharmDx kit was used to measure the expression level of PD-L1. (B) The expression level of tumor mutation burden (TMB) in *KRAS* subtype mutations, including *A146X*, *G12X*, *G13X*, and *Q61X* (n=412). (C) The expression level of PD-L1 in subtype of *KRAS* mutations (n=412). (D) Positive correlation between the expression of TMB and PD-L1 was confirmed by linear analysis (n=168). (E) The proportion of patients with high PD-L1 [tumor proportion score (TPS)  $\geq 50\%$ ] expression in in *KRAS* subtype mutations (n=412). \*,  $P < 0.05$ .

and *CDKN2A*), respectively. The most common mutation subtype was *KRAS/TP53* (n=75, 48.39%), followed by *KRAS* (n=56, 36.13%), *KRAS/STK11* (n=22, 14.19%), and *KRAS/CDKN2A* (n=2, 1.29%) (Figure 5A). Analysis of TMB expression in the 4 groups showed that it was highest in *KRAS/TP53* (Figure 5B). We further analyzed the proportion of subtypes in the *KRAS* and *KRAS/TP53* groups in tissue samples of 155 NSCLC patients. The proportion of *G13X* in the *KRAS* and *KRAS/TP53* groups was 9.6% and 12%, respectively (Figure 5C, 5D). The proportion of *Q61H* in the *KRAS* and *KRAS/TP53* was 4.5% and 2.6%, respectively (Figure 5C, 5D). In conclusion, the composition ratio of *G13X* in *KRAS/TP53* co-mutation was significantly higher than the ratio of *Q61H* in *KRAS* mutation patients.


#### The composition ratio of *G13X* in *KRAS/TP53* co-mutation is significantly higher than *Q61X* in blood

The clinical data of 69 patients with *KRAS* mutation were analyzed. The most common mutation subtype was *KRAS/*


*TP53* (n=32, 46.38%), followed by *KRAS* (n=23, 33.33%), *KRAS/STK11* (n=11, 15.94%), and *KRAS/CDKN2A* (n=3, 4.35%) (Figure 6A). TMB expression in *KRAS/TP53* was the highest (specify) (Figure 6B). We further analyzed the proportion of subtypes in the *KRAS* and *KRAS/TP53* groups in blood samples of 69 NSCLC patients. The proportion of *G13X* in the *KRAS* and *KRAS/TP53* groups was 8.7% and 10%, respectively (Figure 6C, 6D). The proportion of *Q61H* in the *KRAS* and *KRAS/TP53* groups was 7.4% and 3.1%, respectively (Figure 6C, 6D).

## Discussion

*KRAS* mutation occurs in 20–40% of LADCs (30). RAS signaling is associated with various immune-modulating effects, including the regulation of CD8+ lymphocyte infiltration, PD-L1 expression, and myeloid-derived suppressor cell density in the tumor microenvironment (TME) (31–34). Smoking and *KRAS* mutation were positively associated with the expression of PD-L1 on immune cells. Multivariate analysis demonstrated that



**Figure 5** The composition ratio of *G13X* in *KRAS/TP53* comutation is significantly higher than *Q61X* in tissue. (A) The frequency of *KRAS* co-mutation subtype in tissues of 155 non-small cell lung cancer (NSCLC) patients, including *KRAS/TP53* (*KP*), *KRAS/STK11* (*KL*), *KRAS/CDKN2A* (*KC*), and *KRAS* mutation (without *TP53*, *STK11*, and *CDKN2A*); (B) the expression level of tumor mutation burden (TMB) in *KRAS* subtype mutations, including *KL*, *KP*, *KC*, and *KRAS* (n=155); (C) the frequency of *KRAS* subtype mutation in tissues (n=155); (D) the frequency of *KRAS* subtype mutation in tissues with *KRAS/TP53* mutation (n=75). \*,  $P < 0.05$ ; \*\*\*,  $P < 0.001$ .



**Figure 6** The composition ratio of *G13X* in *KRAS/TP53* co-mutation is significantly higher than *Q61X* in blood. (A) The frequency of *KRAS* comutation subtype in blood samples of 69 non-small cell lung cancer (NSCLC) patients, including *KRAS/TP53* (*KP*), *KRAS/STK11* (*KL*), *KRAS/CDKN2A* (*KC*), and *KRAS* mutation (without *TP53*, *STK11*, and *CDKN2A*); (B) the expression level of tumor mutation burden (TMB) in *KRAS* subtype mutations, including *KL*, *KP*, *KC*, and *KRAS* (n=69); (C) the frequency of *KRAS* subtype mutation in blood samples (n=69); (D) the frequency of *KRAS* subtype mutation in blood samples with *KRAS/TP53* mutation (n=32). \*,  $P < 0.05$ ; \*\*\*\*,  $P < 0.0001$ .

*KRAS* mutation and smoking were independent predictors for positive expression of PD-L1 on immune cells (35,36). Patients with *KRAS* mutation and extensive smoking history were more likely to have PD-L1 expression on both tumor cells and immune cells (37). Of patients with *KRAS* mutation, *G12D* has a higher proportion of never-smokers, and smoking is associated with high PD-L1 expression. The patients with *KRAS G12D* mutation were found to have markedly decreased TMB and PD-L1 expression, which was consistent with the conclusions of previous research.

Different *KRAS* mutation subtypes have been confirmed to have different biological characteristics. Three common *G12* mutations are reported to be associated with poor outcomes, including *G12C*, *G12V*, and *G12R* (38,39). In particular, mutations in *G12C* and *G12V* are associated with worse survival compared with other *KRAS* mutation subtypes (40). There was no statistically significant difference in overall survival (OS) between the 3 main subtypes (*G12C* vs. *G12D* vs. *G12V*,  $P=0.81$ ) and codons (12 vs. 13 vs. 61,  $P=0.36$ ) of *KRAS* mutations. Codon 13 had a lower estimated 2-year OS rate of 38.6% (95% CI: 21.0–55.9) and codon 61 had a relatively higher 2-year OS rate of 65.0% (95% CI: 42.5–80.5) (14).

On May 28, 2021, the FDA granted accelerated approval for sotorasib (Lumakras™, Amgen, Inc.), a *RAS* GTPase-family inhibitor, for patients with *KRAS G12C*-mutated locally advanced or metastatic NSCLC who have received at least 1 prior systemic therapy (18). However, the majority of *KRAS* mutations remain not directly targetable (41). Therefore, we aimed to explore the immunological properties of different *KRAS* subtypes. We demonstrated that patients with *KRAS Q61* mutation and patients with *KRAS G13* mutation had markedly decreased TMB and PD-L1 expression.

Mutations in *KRAS*, mesenchymal-epithelial transition (MET), and *TP53* were significantly correlated with high PD-L1 expression (each  $P<0.001$ ,  $q<0.001$ ), while *STK11* and *EGFR* mutations correlated with low PD-L1 expression ( $P<0.001$ , respectively) (42). *KRAS* mutation is associated with an increase in the ratio of PD-L1 and CD8+ tumor-infiltrating lymphocytes (TILs), increased TMB, and immunogenicity (20). *KRAS* mutations were divided into 3 subgroups according to the co-mutation types in *KRAS*-mutated lung cancer: *KRAS/TP53* (*KP*), *KRAS/STK11* (*KL*), and *KRAS/CDKN2A* (*KC*) (26,28,43,44). *KL* tumors demonstrated lower levels of immune checkpoint effector molecules, such as PD-L1. *KP* tumors expressed higher levels of immune markers, somatic mutations, inflammatory

markers, and improved recurrence-free survival (45). However, whether the mutant subtypes of *KRAS* could predict clinical response to immune checkpoint inhibitions (ICIs) remains unclear. Consistent with previous studies, our study found that *TP53/KRAS* co-mutation can significantly increase TMB. Meanwhile, we found that the expression ratio of *G13* in the *KRAS/TP53* group was higher than that in the *KRAS* group, although this requires further validation in larger datasets.

Several studies and data from major trials have demonstrated the relationship between high TMB and response to ICIs in populations (46). TMB has also been shown to be correlated with better progression-free survival (PFS) of ICIs in NSCLC. In patients treated with PD-1/PD-L1 inhibitors ( $n=1,290$ , 31.7%), TMB of 20 or more was associated with superior OS [16.8 months (95% CI: 11.6–24.9) vs. 8.5 months (95% CI: 7.6–9.7),  $P<0.001$ ] and longer time receiving therapy [7.8 months (95% CI: 5.5–11.1) vs. 3.3 months (95% CI: 2.8–3.7),  $P<0.001$ ] compared to TMB less than 20 (47). PD-L1 has also been approved by the FDA as a diagnostic marker for checkpoint inhibitors (22,48). However, not all patients with high expression of PD-L1 respond to therapy or demonstrate a durable clinical benefit. KEYNOTE-024 demonstrated better OS for pembrolizumab vs. chemotherapy in patients with high PD-L1 expression (PD-L1 expression  $\geq 50\%$ ) (49,50). Therefore, we further explored the proportion of PD-L1 expression in each subtype of *KRAS* mutation (PD-L1  $\geq 50\%$ ). The proportion of PD-L1 (TPS  $\geq 50\%$ ) was 46% and 16% in *G13X* and *Q61X*, respectively. This also suggested that in patients with *KRAS* mutations, the *G13X* group could achieve better survival through immunotherapy, while the *Q61X* group gained poorer survival benefit.

The comprehensive evaluation of the expression level of both TMB and PD-L1 may provide greater guidance value for patient response to immunotherapy. We confirmed that *G13X* subtype expressed both higher levels of TMB and PD-L, while *Q61X* expressed lower levels of both TMB and PD-L1. Subtype alterations in *KRAS*-mutant NSCLC may be predictors of anti-PD-1/PD-L1 treatment sensitivity, which could also provide more individualized treatment for patients with *KRAS*-mutant lung cancer.

## Conclusions

Our research confirmed the diversity of genetic backgrounds in different *KRAS* subtypes. We have



demonstrated the low level of TMB and expression of PD-L1 in *KRAS Q61X*-mutant lung cancer and the high level of TMB and expression of PD-L1 in *KRAS G13X*-mutant lung cancer. Our conclusions were consistently verified in tissue and blood samples, and supports the feasibility of NGS verification in blood. The subtype of *KRAS* mutation could be a potential therapeutic biomarker in *KRAS*-mutant lung cancer, providing better individualized treatment strategies for lung cancer patients.

## Acknowledgments

The authors appreciate the academic support from the AME Lung Cancer Collaborative Group. We would like to thank all the colleagues in our research team.

**Funding:** This study was funded by National Natural Science Foundation of China (No. 82072564), Project of Shanghai Natural Science Foundation (No. 20ZR1452000), Shanghai youth talent support program, Shanghai Chest Hospital Project of Collaborative Innovative Grant (No. YJT20191015), Lian Yun Gang Shi Hui Lan Public Foundation (No. HL-HS2020-65), Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG) and Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (No. 2017B030314120), National Multi-disciplinary Treatment Project for Major Diseases (No. 2020NMDTP).

## Footnote

**Reporting Checklist:** The authors have completed the MDAR reporting checklist. Available at <https://tldr.amegroups.com/article/view/10.21037/tlcr-22-88/rc>

**Data Sharing Statement:** Available at <https://tldr.amegroups.com/article/view/10.21037/tlcr-22-88/dss>

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at <https://tldr.amegroups.com/article/view/10.21037/tlcr-22-88/coif>). The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was approved by the institutional review board at Shanghai Jiao Tong University, Shanghai Chest Hospital (No. IS21126).

It was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Individual consent for this retrospective analysis was waived.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.


## References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020;70:7-30.
2. Grommes C, DeAngelis LM. Primary CNS Lymphoma. *J Clin Oncol* 2017;35:2410-8.
3. Jordan EJ, Kim HR, Arcila ME, et al. Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. *Cancer Discov* 2017;7:596-609.
4. Downward J. Targeting RAS signalling pathways in cancer therapy. *Nat Rev Cancer* 2003;3:11-22.
5. Heymach JV, Nilsson M, Blumenschein G, et al. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. *Clin Cancer Res* 2006;12:4441s-5s.
6. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med* 2013;368:2385-94.
7. Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. *Cancer Discov* 2013;3:630-5.
8. Cox AD, Fesik SW, Kimmelman AC, et al. Drugging the undruggable RAS: Mission possible? *Nat Rev Drug Discov* 2014;13:828-51.
9. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature* 2014;511:543-50.
10. Wood K, Hensing T, Malik R, et al. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. *JAMA Oncol* 2016;2:805-12.
11. Tape CJ, Ling S, Dimitriadis M, et al. Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation.

- Cell 2016;165:910-20.
12. Garrido P, Olmedo ME, Gómez A, et al. Treating KRAS-mutant NSCLC: latest evidence and clinical consequences. *Ther Adv Med Oncol* 2017;9:589-97.
  13. Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. *Clin Cancer Res* 2012;18:6169-77.
  14. El Osta B, Behera M, Kim S, et al. Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. *J Thorac Oncol* 2019;14:876-89.
  15. Reck M, Carbone DP, Garassino M, et al. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. *Ann Oncol* 2021;32:1101-10.
  16. Govindan R, Fakih M, Price T, et al. Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours. *Ann Oncol* 2019;30:v163-4.
  17. Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature* 2019;575:217-23.
  18. Palma G, Khurshid F, Lu K, et al. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes. *NPJ Precis Oncol* 2021;5:98.
  19. Negrao MV, Skoulidis F, Montesin M, et al. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. *J Immunother Cancer* 2021;9:e002891.
  20. Liu C, Zheng S, Jin R, et al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. *Cancer Lett* 2020;470:95-105.
  21. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *N Engl J Med* 2015;373:1627-39.
  22. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. *Lancet* 2016;387:1837-46.
  23. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet* 2017;389:255-65.
  24. Passiglia F, Cappuzzo F, Alabiso O, et al. Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations. *Br J Cancer* 2019;120:57-62.
  25. Jeanson A, Tomasini P, Souquet-Bressand M, et al. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). *J Thorac Oncol* 2019;14:1095-101.
  26. Skoulidis F, Byers LA, Diao L, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. *Cancer Discov* 2015;5:860-77.
  27. Huang L, Guo Z, Wang F, et al. KRAS mutation: from undruggable to druggable in cancer. *Signal Transduct Target Ther* 2021;6:386.
  28. Dong ZY, Zhong WZ, Zhang XC, et al. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. *Clin Cancer Res* 2017;23:3012-24.
  29. Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. *Cancer Discov* 2018;8:822-35.
  30. Ricciuti B, Leonardi GC, Metro G, et al. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. *Expert Rev Respir Med* 2016;10:53-68.
  31. Adderley H, Blackhall FH, Lindsay CR. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. *EBioMedicine* 2019;41:711-6.
  32. Lee CK, Man J, Lord S, et al. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. *JAMA Oncol* 2018;4:210-6.
  33. Dias Carvalho P, Guimarães CF, Cardoso AP, et al. KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment. *Cancer Res* 2018;78:7-14.
  34. Uprety D, Adjei AA. KRAS: From undruggable to a druggable Cancer Target. *Cancer Treat Rev* 2020;89:102070.
  35. Tseng JS, Yang TY, Wu CY, et al. Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients. *J Immunother*

- 2018;41:292-9.
36. Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. *Tumori* 2012;98:751-5.
  37. Song P, Guo L, Li W, et al. Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer. *J Immunother* 2019;42:23-8.
  38. Yu HA, Sima CS, Shen R, et al. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. *J Thorac Oncol* 2015;10:431-7.
  39. Uras IZ, Moll HP, Casanova E. Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future. *Int J Mol Sci* 2020;21:4325.
  40. Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. *J Natl Cancer Inst* 2012;104:228-39.
  41. Drosten M, Barbacid M. Targeting the MAPK Pathway in KRAS-Driven Tumors. *Cancer Cell* 2020;37:543-50.
  42. Schoenfeld AJ, Rizvi H, Bandlamudi C, et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. *Ann Oncol* 2020;31:599-608.
  43. La Fleur L, Falk-Sörqvist E, Smeds P, et al. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. *Lung Cancer* 2019;130:50-8.
  44. Schabath MB, Welsh EA, Fulp WJ, et al. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. *Oncogene* 2016;35:3209-16.
  45. Galan-Cobo A, Sitthideatphaiboon P, Qu X, et al. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma. *Cancer Res* 2019;79:3251-67.
  46. Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. *Ann Oncol* 2019;30:44-56.
  47. Singal G, Miller PG, Agarwala V, et al. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. *JAMA* 2019;321:1391-9.
  48. Wu SP, Liao RQ, Tu HY, et al. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. *J Thorac Oncol* 2018;13:521-32.
  49. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. *N Engl J Med* 2016;375:1823-33.
  50. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. *Lancet* 2019;393:1819-30.
- (English Language Editor: A. Muylwyk)

**Cite this article as:** Yang Y, Shen S, Sun Y, Husain H, Zhou H, Lu S, Li Z. The relationship between different subtypes of *KRAS* and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients. *Transl Lung Cancer Res* 2022;11(2):213-223. doi: 10.21037/tlcr-22-88



**Figure S1** Representative images of PD-L1 expression (200 $\times$ ). PD-L1 protein expression was evaluated by IHC. The PD-L1 clone 22C3 pharmDx kit was used to measure the expression level of PD-L1. PD-L1 expression was assessed by the percentage of tumor cells with any intensity of PD-L1 membrane staining out of all tumor cells